258 related articles for article (PubMed ID: 35286152)
1. Risk and Outcome of Breakthrough COVID-19 Infections in Vaccinated Patients With Cancer: Real-World Evidence From the National COVID Cohort Collaborative.
Song Q; Bates B; Shao YR; Hsu FC; Liu F; Madhira V; Mitra AK; Bergquist T; Kavuluru R; Li X; Sharafeldin N; Su J; Topaloglu U
J Clin Oncol; 2022 May; 40(13):1414-1427. PubMed ID: 35286152
[TBL] [Abstract][Full Text] [Related]
2. Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.
Gong IY; Vijenthira A; Powis M; Calzavara A; Patrikar A; Sutradhar R; Hicks LK; Wilton D; Singh S; Krzyzanowska MK; Cheung MC
JAMA Oncol; 2023 Mar; 9(3):386-394. PubMed ID: 36580318
[TBL] [Abstract][Full Text] [Related]
3. Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US.
Sun J; Zheng Q; Madhira V; Olex AL; Anzalone AJ; Vinson A; Singh JA; French E; Abraham AG; Mathew J; Safdar N; Agarwal G; Fitzgerald KC; Singh N; Topaloglu U; Chute CG; Mannon RB; Kirk GD; Patel RC;
JAMA Intern Med; 2022 Feb; 182(2):153-162. PubMed ID: 34962505
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.
Wang L; Kaelber DC; Xu R; Berger NA
Blood Rev; 2022 Jul; 54():100931. PubMed ID: 35120771
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
7. Community risks for SARS-CoV-2 infection among fully vaccinated US adults by rurality: A retrospective cohort study from the National COVID Cohort Collaborative.
Anzalone AJ; Sun J; Vinson AJ; Beasley WH; Hillegass WB; Murray K; Hendricks BM; Haendel M; Geary CR; Bailey KL; Hanson CK; Miele L; Horswell R; McMurry JA; Porterfield JZ; Vest MT; Bunnell HT; Harper JR; Price BS; Santangelo SL; Rosen CJ; McClay JC; Hodder SL;
PLoS One; 2023; 18(1):e0279968. PubMed ID: 36603014
[TBL] [Abstract][Full Text] [Related]
8. Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, January-March 2021.
Sadigh KS; Kugeler KJ; Bressler S; Massay SC; Schmoll E; Milroy L; Cavanaugh AM; Sierocki A; ; Fischer M; Nolen LD
BMC Infect Dis; 2022 Sep; 22(1):718. PubMed ID: 36050630
[TBL] [Abstract][Full Text] [Related]
9. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
[TBL] [Abstract][Full Text] [Related]
10. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
11. Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US Between December 2020 and November 2021.
Wang W; Kaelber DC; Xu R; Berger NA
JAMA Oncol; 2022 Jul; 8(7):1027-1034. PubMed ID: 35394485
[TBL] [Abstract][Full Text] [Related]
12. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study.
Ge J; Digitale JC; Pletcher MJ; Lai JC;
Hepatology; 2023 Mar; 77(3):834-850. PubMed ID: 36799617
[TBL] [Abstract][Full Text] [Related]
14. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
15. Effects of Antibody Response after Booster Vaccination on SARS-CoV-2 Breakthrough Infections and Disease Outcomes in Advanced Cancer Patients: A Prospective Analysis of the Vax-on-Third Study.
Nelli F; Fabbri A; Virtuoso A; Giannarelli D; Giron Berrios JR; Marrucci E; Fiore C; Schirripa M; Signorelli C; Chilelli MG; Primi F; Pessina G; Natoni F; Silvestri MA; Ruggeri EM
Curr Oncol; 2023 May; 30(5):5103-5115. PubMed ID: 37232844
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States.
Coburn SB; Humes E; Lang R; Stewart C; Hogan BC; Gebo KA; Napravnik S; Edwards JK; Browne LE; Park LS; Justice AC; Gordon KS; Horberg MA; Certa JM; Watson E; Jefferson CR; Silverberg MJ; Skarbinski J; Leyden WA; Williams CF; Althoff KN;
JAMA Netw Open; 2022 Jun; 5(6):e2215934. PubMed ID: 35671054
[TBL] [Abstract][Full Text] [Related]
17. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
Stowe J; Miller E; Andrews N; Whitaker HJ
PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections - Risk Factors and Vaccine Effectiveness.
Liu C; Lee J; Ta C; Soroush A; Rogers JR; Kim JH; Natarajan K; Zucker J; Weng C
medRxiv; 2021 Oct; ():. PubMed ID: 34642696
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium.
Stouten V; Hubin P; Haarhuis F; van Loenhout JAF; Billuart M; Brondeel R; Braeye T; Van Oyen H; Wyndham-Thomas C; Catteau L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458532
[TBL] [Abstract][Full Text] [Related]
20. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
